US2017044257A1PendingUtilityA1
Methods to manipulate alpha-fetoprotein (afp)
Assignee: BRIGHAM & WOMENS HOSPITAL INCPriority: Apr 25, 2014Filed: Apr 21, 2015Published: Feb 16, 2017
Est. expiryApr 25, 2034(~7.8 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 35/00C07K 16/44C07K 2317/77C07K 2317/76C07K 16/283A61K 39/3955A61K 45/06
42
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
As demonstrated herein, soluble human FcRn binds to AFP with affinities greater than observed with albumin, and is able to interfere with FcRn-mediated protection of and functional associations with IgG. Accordingly, provided herein, in some aspects, are compositions and methods to inhibit FcRn and AFP interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate FcRn and AFP interactions in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels increasing with immunosuppression.
Claims
exact text as granted — not AI-modified1 . A pharmaceutical composition comprising an inhibitor of AFP-FcRn and a pharmaceutically acceptable carrier, wherein said inhibitor of AFP-FcRn inhibits binding between alpha-fetoprotein (AFP) and FcRn.
2 . The pharmaceutical composition of claim 1 , wherein the inhibitor of AFP-FcRn comprises a T451I and/or D536V polymorphism of wild-type AFP.
3 . The pharmaceutical composition of any one of claims 1 - 2 , wherein the inhibitor of AFP-FcRn inhibits binding between Y521 and/or V522 of AFP and R42 of FcRn.
4 . The pharmaceutical composition of any one of claims 1 - 3 , wherein the inhibitor of AFP-FcRn inhibits binding between P492 of AFP and R69 of FcRn.
5 . The pharmaceutical composition of any one of claims 1 - 4 , wherein the inhibitor of AFP-FcRn inhibits binding between Q441 and/or V493 of AFP and E44 of FcRn.
6 . The pharmaceutical composition of any one of claims 1 - 5 , wherein the inhibitor of AFP-FcRn inhibits binding between H534 and/or E589 of AFP and N173 of FcRn.
7 . The pharmaceutical composition of any one of claims 1 - 6 , wherein the inhibitor of AFP-FcRn inhibits binding between the hydrophobic core of AFP and FcRn.
8 . The pharmaceutical composition of any one of claims 1 - 7 , wherein the inhibitor of AFP-FcRn inhibits binding between L484, V493, V497, and/or F512 of AFP and V57, W59, and/or W61 of FcRn.
9 . The pharmaceutical composition of any one of claims 1 - 8 , wherein the inhibitor of AFP-FcRn inhibits binding between T443 of AFP and E62 and/or W59 of FcRn.
10 . The pharmaceutical composition of any one of claims 1 - 9 , wherein the inhibitor of AFP-FcRn inhibits binding between D529 of AFP and S230 of FcRn.
11 . The pharmaceutical composition of any one of claims 1 - 10 , wherein the inhibitor of AFP-FcRn inhibits binding between S527 and/or D528 of AFP and E50 and/or 67Y of β2m complexed with FcRn.
12 . The pharmaceutical composition of any one of claims 1 - 11 , wherein the inhibitor of AFP-FcRn inhibits binding between R604 of AFP and the carbonyl oxygen at E50 of β2m complexed with FcRn.
13 . The pharmaceutical composition of any one of claims 1 - 12 , wherein the inhibitor of AFP-FcRn inhibits binding between Q597 of AFP and E69 of β2m complexed with FcRn.
14 . The pharmaceutical composition of any one of claims 1 - 13 , wherein the inhibitor of AFP-FcRn inhibits binding between E106 of AFP and H161 of FcRn.
15 . The pharmaceutical composition of any one of claims 1 - 14 , wherein the inhibitor of AFP-FcRn inhibits binding between S135 of AFP and H161 of FcRn.
16 . The pharmaceutical composition of any one of claims 1 - 15 , wherein the inhibitor of AFP-FcRn inhibits binding between F531, F533, F552, and/or F575 of AFP and W53 of FcRn.
17 . The pharmaceutical composition of any one of claims 1 - 16 , wherein the inhibitor of AFP-FcRn is an antibody or antigen-binding fragment thereof, a small molecule compound, or an RNA or DNA aptamer.
18 . The pharmaceutical composition of claim 17 , wherein the antibody or antigen-binding fragment thereof is a chimeric, humanized, or completely human antibody or antigen-binding fragment thereof.
19 . The pharmaceutical composition of any one of claims 1 - 18 , wherein the inhibitor of AFP-FcRn inhibits or blocks the AFP binding site on FcRn.
20 . A pharmaceutical composition comprising an AFP-FcRn potentiator and a pharmaceutically acceptable carrier.
21 . The pharmaceutical composition of claim 20 , wherein the AFP-FcRn potentiator comprises a G109R, R487S, and/or S445L polymorphism of wild-type alpha-fetoprotein (AFP) that increases AFP-FcRn binding.
22 . The pharmaceutical composition of any one of claims 20 - 21 , wherein the AFP-FcRn potentiator enhances binding between Y521 and/or V522 of AFP and R42 of FcRn.
23 . The pharmaceutical composition of any one of claims 20 - 22 , wherein the AFP-FcRn potentiator enhances binding between P492 of AFP and R69 of FcRn.
24 . The pharmaceutical composition of any one of claims 20 - 23 , wherein the AFP-FcRn potentiator enhances binding between Q441 and/or V493 of AFP and E44 of FcRn.
25 . The pharmaceutical composition of any one of claims 20 - 24 , wherein the AFP-FcRn potentiator enhances binding between H534 and/or E589 of AFP and N173 of FcRn.
26 . The pharmaceutical composition of any one of claims 20 - 25 , wherein the AFP-FcRn potentiator enhances binding between the hydrophobic core of AFP and FcRn.
27 . The pharmaceutical composition of any one of claims 20 - 26 , wherein the AFP-FcRn potentiator enhances binding between L484, V493, V497, and/or F512 of AFP and V57, W59, and/or W61 of FcRn.
28 . The pharmaceutical composition of any one of claims 20 - 27 , wherein the AFP-FcRn potentiator enhances binding between T443 of AFP and E62 and/or W59 of FcRn.
29 . The pharmaceutical composition of any one of claims 20 - 28 , wherein the AFP-FcRn potentiator enhances binding between D529 of AFP and S230 of FcRn.
30 . The pharmaceutical composition of any one of claims 20 - 29 , wherein the AFP-FcRn potentiator enhances binding between S527 and/or D528 of AFP and E50 and/or 67Y of β2m complexed with FcRn.
31 . The pharmaceutical composition of any one of claims 20 - 30 , wherein the AFP-FcRn potentiator enhances binding between R604 of AFP and the carbonyl oxygen at E50 β2m complexed with FcRn.
32 . The pharmaceutical composition of any one of claims 20 - 31 , wherein the AFP-FcRn potentiator enhances binding between Q597 of AFP and E69 of β2m complexed with FcRn.
33 . The pharmaceutical composition of any one of claims 20 - 32 , wherein the AFP-FcRn potentiator enhances binding between E106 of AFP and H161 of FcRn.
34 . The pharmaceutical composition of any one of claims 20 - 33 , wherein the AFP-FcRn potentiator enhances binding between S135 of AFP and H161 of FcRn.
35 . The pharmaceutical composition of any one of claims 20 - 34 , wherein the AFP-FcRn potentiator enhances binding between 531, F533, F552, and/or F575 of AFP and W53 of FcRn.
36 . The pharmaceutical composition of any one of claims 20 - 35 , wherein the AFP-FcRn potentiator is an antibody or antigen-binding fragment thereof, a small molecule compound, an RNA or DNA aptamer, or an AFP functional fragment.
37 . The pharmaceutical composition of claim 36 , wherein the antibody or antigen-binding fragment thereof is a chimeric, humanized, or completely human antibody or antigen-binding fragment thereof.
38 . The pharmaceutical composition of any one of claims 20 - 37 , wherein the AFP-FcRn potentiator binds FcRn and mimics AFP binding.
39 . The pharmaceutical composition of any one of claims 20 - 37 , wherein the AFP-FcRn potentiator binds or physically interacts with AFP or FcRn, and enhances or promotes interactions between AFP and FcRn.
40 . The pharmaceutical composition of claim 36 , wherein the AFP-functional fragment comprises Y521 and/or V522 of AFP and can interact with R42 of FcRn.
41 . The pharmaceutical composition of any one of claim 36 or 40 , wherein the AFP-functional fragment comprises P492 of AFP and can interact with R69 of FcRn.
42 . The pharmaceutical composition of any one of claim 36 or 40 - 41 , wherein the AFP-functional fragment comprises Q441 and/or V493 of AFP and can interact with E44 of FcRn.
43 . The pharmaceutical composition of any one of claim 36 or 40 - 42 , wherein the AFP-functional fragment comprises H534 and/or E589 of AFP and can interact with N173 of FcRn.
44 . The pharmaceutical composition of any one of claim 36 or 40 - 43 , wherein the AFP-functional fragment comprises L484, V493, V497, and/or F512 of AFP and can interact with V57, W59, and/or W61 of FcRn.
45 . The pharmaceutical composition of any one of claim 36 or 40 - 44 , wherein the AFP-functional fragment comprises T443 of AFP and can interact with E62 and/or W59 of FcRn.
46 . The pharmaceutical composition of any one of claim 36 or 40 - 45 , wherein the AFP-functional fragment comprises D529 of AFP and can interact with S230 of FcRn.
47 . The pharmaceutical composition of any one of claim 36 or 40 - 46 , wherein the AFP-functional fragment comprises S527 and/or D528 of AFP and can interact with E50 and/or 67Y of β2m complexed with FcRn.
48 . The pharmaceutical composition of any one of claim 36 or 40 - 47 , wherein the AFP-functional fragment comprises R604 of AFP and can interact with the carbonyl oxygen at E50 of β2m complexed with FcRn.
49 . The pharmaceutical composition of any one of claim 36 or 40 - 48 , wherein the AFP-functional fragment comprises Q597 of AFP and can interact with E69 of β2m complexed with FcRn.
50 . The pharmaceutical composition of any one of claim 36 or 40 - 49 , wherein the AFP-functional fragment comprises E106 of AFP and can interact with H161 of FcRn.
51 . The pharmaceutical composition of any one of claim 36 or 40 - 50 , wherein the AFP-functional fragment comprises S135 of AFP and can interact with H161 of FcRn.
52 . The pharmaceutical composition of any one of claim 36 or 40 - 51 , wherein the AFP-functional fragment comprises F531, F533, F552, and/or F575 of AFP and can interact with W53 of FcRn.
53 . A method to inhibit or reduce FcRn and alpha-fetoprotein (AFP) interactions in a disease or disorder associated with elevated AFP levels comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an AFP-FcRn inhibitor of any one of claims 1 - 19 to a subject in need thereof.
54 . The method of claim 53 , wherein the subject has or has been diagnosed with cancer.
55 . The method of any one of claim 53 or 54 , wherein the subject has or has been diagnosed with a cancer or tumor of primitive origin, a tumor of liver origin, such as a hepatoma, a tumor of biliary origin, such as cholangiocarcinoma, stomach cancer, pancreatic cancer, or a teratocarcinoma.
56 . The method of any one of claims 53 - 55 , further comprising administering an anti-cancer therapy or agent to the subject.
57 . The method of any one of claims 53 - 56 , further comprising administering a tumor or cancer antigen.
58 . A method to increase or potentiate FcRn and alpha-fetoprotein (AFP) interactions in diseases or disorders associated with decreased AFP levels or where increasing AFP levels is beneficial comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an AFP-FcRn potentiator of any one of claims 20 - 52 to a subject in need thereof.
59 . The method of claim 58 , wherein the subject in need is pregnant or is at risk for having a problem with establishing and/or maintaining a pregnancy.
60 . The method of claim 58 , wherein the subject has or has been diagnosed with an autoimmune disease or disorder.
61 . The method of claim 58 , wherein the subject has or has been diagnosed with host versus graft disease (HVGD), is an organ or tissue transplant recipient, or a recipient of an allogenic transplant.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.